Zobrazeno 1 - 2
of 2
pro vyhledávání: ''
Autor:
Sally Tan, Pasi A. Jänne, John J. Wright, Katherine Larrabee, Hao Guo, Eric P. Winer, Sara M. Tolaney, Eliezer M. Van Allen, Elena Ivanova, Ian E. Krop, Beth Overmoyer, William H. Barry, Jane E. Brock, Geoffrey I. Shapiro, Cloud P. Paweletz, Nikhil Wagle
Publikováno v:
Investigational New Drugs
SummaryBackground MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests t
Autor:
Alex A. Adjei, Paolo Andrea Zucali, Julie Means-Powell, Maria Lamar, Brian Schwartz, Armando Santoro, Laura W. Goff, Robert E. Martell, Ronald E. Savage, Matteo Simonelli, Jeffrey A. Sosman, Grace K. Dy, Wen Wee Ma, Muhammad Wasif Saif, Feng Chai, Igor Puzanov
Publikováno v:
Investigational New Drugs
SummaryPurpose This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients with advanced solid tumors. Materials and Methods A standard 3